drugset / Trial / NCT06725264
Tyrosine Kinase 2 (TYK2) for GA and CS
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To investigate the role of an oral TYK2 inhibitor for the treatment of patients with moderate to severe sarcoidosis with cutaneous involvement (CSAMI score of 10 or greater) and GA (defined as a BSA involvement of at least 5%), which are difficult to treat.
Timeline
- Start
- 2025-03
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRAVACITINIB | Small molecule | 6 mg | Oral |